Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GIR-M52H3 | Mouse | Mouse GITR / TNFRSF18 Protein, His Tag |  |
|
|
| GIR-H82E1 | Human | Biotinylated Human GITR / TNFRSF18 Protein, His,Avitag™ (MALS verified) |  |
|
|
| GIR-C52H6 | Canine | Canine GITR / TNFRSF18 Protein, His Tag |  |
|
|
| GIR-H82F7 | Human | Biotinylated Human GITR / TNFRSF18 Protein, Fc,Avitag™ |  |
|
|
| GIR-H525a | Human | Human GITR / TNFRSF18 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| GIR-H5254 | Human | Human GITR / TNFRSF18 Protein, Fc Tag |  |
|
|
| GIR-C5255 | Rhesus macaque | Rhesus macaque GITR / TNFRSF18 Protein, Fc Tag |  |
|
|
| GIR-R5222 | Rat | Rat GITR / TNFRSF18 Protein, His Tag |  |
|
|
| GIR-H5228 | Human | Human GITR / TNFRSF18 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Human GITR Ligand, Fc Tag at 10 μg/mL (100 μL/well) can bind Biotinylated Human GITR, His,Avi tag™ (Cat. No. GIR-H82E1) with a linear range of 0.039-0.625 μg/mL (QC tested).
The purity of Biotinylated Human GITR Protein, His,Avitag (Cat. No. GIR-H82E1) is more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BMS-986156 | BMS-986156 | Phase 2 Clinical | Bristol-Myers Squibb Company | Liver Neoplasms; Solid tumours; Thoracic Neoplasms; Neoplasms; Lung Neoplasms | Details |
| Ragifilimab | INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Neoplasms; Neoplasm Metastasis | Details |
| Anti-GITR antibody (BMS) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
| REGN-6569 | REGN-6569; REGN6569 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Squamous Cell Carcinoma of Head and Neck | Details |
| IBI-102 | IBI102; IBI-102 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms | Details |
| GWN-323 | GWN-323 | Phase 1 Clinical | Novartis Pharma Ag | Solid tumours; Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
